- Home
- ROIV vs EAT Comparison
ROIV vs EAT Comparison
Compare ROIV & EAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | EAT |
|---|---|---|
| Founded | 2014 | 1975 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.7B | 8.1B |
| IPO Year | 2021 | 1994 |
Fundamental Metrics
Financial Performance| Metric | ROIV | EAT |
|---|---|---|
| Price | $39.26 | $198.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 23 |
| Target Price | $50.64 | ★ $264.73 |
| AVG Volume (30 Days) | ★ 7.7M | 1.4M |
| Earning Date | 11-09-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 30.65 |
| EPS | N/A | ★ 2.64 |
| Revenue | $8,260,000.00 | ★ $5,807,400,000.00 |
| Revenue This Year | $1,827.44 | $8.63 |
| Revenue Next Year | $196.90 | $2.94 |
| P/E Ratio | ★ N/A | $74.22 |
| Revenue Growth | N/A | ★ 7.86 |
| 52 Week Low | $19.96 | $114.73 |
| 52 Week High | $42.50 | $254.99 |
Technical Indicators
Market Signals| Indicator | ROIV | EAT |
|---|---|---|
| Relative Strength Index (RSI) | 56.04 | 47.18 |
| Support Level | $33.11 | $186.08 |
| Resistance Level | $42.50 | $212.23 |
| Average True Range (ATR) | 1.49 | 11.59 |
| MACD | 0.38 | -1.02 |
| Stochastic Oscillator | 55.76 | 26.58 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About EAT Brinker International Inc.
Brinker International is a leading casual dining operator and franchisor. Chili's, its largest banner and the second-largest casual dining concept in the US, is known for its American/Southwest-inspired menu. In fiscal 2026, the segment generated $5.3 billion in revenue (92% of consolidated sales) across 1,114 company-owned restaurants in the US and 469 franchised locations (the bulk of which are in international markets). The Italian casual-dining concept Maggiano's accounts for the remainder of the business, with 52 domestic units.